Asset
LACUTAMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03902184 | phase2 | completed | 2019-05-22 | 2026-01-08 | Innate Pharma | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma |
| NCT05321147 | phase1 | completed | 2022-03-17 | 2023-11-19 | Innate Pharma | Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 |
| NCT02593045 | phase1 | completed | 2015-10-01 | 2020-04-01 | Innate Pharma | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) |
FDA applications (0)
This company has no applications containing this asset.